 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
 |
Analyst Conference Summary
biotechnology
Ligand Pharmaceuticals
LGND
conference date: August 7, 2025
for quarter ending: June 30, 2025 (second quarter, Q2 2025)
Overview:
Basic data (GAAP):
Revenue
Net Income
EPS (Earnings per Share)
Guidance:
Conference Highlights:
Q&A:
OpenIcon Analyst Conference Summaries Main Page
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALNY |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BLRX |
| BIIB |
| BMY |
| CBIO |
| CCCC |
| CLDX |
| CDTX |
| FATE |
| GILD |
| GLYC |
| ILMN |
| INCY |
| INO |
| IONS |
| MCHP |
| MRNA |
| PLX |
| REGN |
| RNA |
| RXRX |
| SAGE |
| SANA |
| VSTM |
| VRTX |
Disclaimer: My analyst call summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2025 William P. Meyers